Title
The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein

Permalink
https://escholarship.org/uc/item/82c7d83v

Journal
Journal of Thrombosis and Haemostasis, 15(6)

ISSN
1538-7933

Authors
Leksa, NC
Chiu, PL
Bou-Assaf, GM
et al.

Publication Date
2017-06-01

DOI
10.1111/jth.13700

Peer reviewed
The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein


Biogen, Cambridge; Department of Cell Biology, Harvard Medical School, Boston, MA; Molecular Biophysics & Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA


Essentials
- Recombinant factor VIII (rFVIII) Fc fusion protein has a 1.5-fold longer half-life than rFVIII.
- Five orthogonal methods were used to characterize the structure of rFVIIIFc compared to rFVIII.
- The C-terminal Fc fusion does not perturb the structure of FVIII in rFVIIIFc.
- The FVIII and Fc components of rFVIIIFc are flexibly tethered and functionally independent.

Summary. Background: Fusion of the human IgG1 Fc domain to the C-terminal C2 domain of B-domain-deleted (BDD) factor VIII (FVIII) results in the recombinant FVIII Fc (rFVIIIFc) fusion protein, which has a 1.5-fold longer half-life in humans. Objective: To assess the structural properties of rFVIIIFc by comparing its constituent FVIII and Fc elements with their respective isolated components, and evaluating their structural independence within rFVIIIFc. Methods: rFVIIIFc and its isolated FVIII and Fc components were compared by the use of hydrogen–deuterium exchange mass spectrometry (HDX-MS). The structure of rFVIIIFc was also evaluated by the use of X-ray crystallography, small-angle X-ray scattering (SAXS), and electron microscopy (EM). The degree of steric interference by the appended Fc domain was assessed by EM and surface plasmon resonance (SPR). Results: HDX-MS analysis of rFVIIIFc revealed that fusion caused no structural perturbations in FVIII or Fc. The rFVIIIFc crystal structure showed that the FVIII component is indistinguishable from published BDD FVIII structures. The Fc domain was not observed, indicating high mobility. SAXS analysis was consistent with an ensemble of rigid-body models in which the Fc domain exists in a largely extended orientation relative to FVIII. Binding of Fab fragments of anti-C2 domain antibodies to BDD FVIII was visualized by EM, and the affinities of the corresponding intact antibodies for BDD FVIII and rFVIIIFc were comparable by SPR analysis. Conclusions: The FVIII and Fc components of rFVIIIFc are structurally indistinguishable from their isolated constituents, and show a high degree of structural independence, consistent with the functional comparability of rFVIIIFc and unmodified FVIII.

Keywords: B-domain-deleted factor VIII; bleeding; factor VIII; hemophilia A; rFVIIIFc protein.

Introduction
Hemophilia A is an X-linked bleeding disorder caused by a functional deficiency of coagulation factor VIII (FVIII) [1]. Individuals with hemophilia A are treated with intravenous infusions of FVIII. For severe hemophilia A, routine prophylaxis entails frequent injections, typically three
times weekly or every other day, depending on an individual's pharmacokinetic (PK) profile [2,3]. To increase FVIII activity levels, efforts were initiated to develop long-acting FVIII variants, which would also allow for less frequent injections [4]. Strategies for extending the circulating half-life of FVIII include the generation of a variety of FVIII–polyethylene glycol (PEG) adducts [5–9] and fusion of an IgG1 Fc domain [10]. The recombinant FVIII Fc (rFVIII(Fc)) fusion protein, in which the Fc domain is fused to the C terminus of B-domain-deleted (BDD) FVIII, has been extensively characterized. Importantly, the specific activity of rFVIIIFc and its affinity for von Willebrand factor (VWF) are comparable to those of other recombinant FVIII products [11]. Preclinical animal studies have shown that rFVIIIFc is well tolerated in both monkeys and rats [12], and clinical data from the ALONG and ASPIRE trials confirm the long-term safety of rFVIIIFc [13].

Although the in vivo efficacy, biochemical properties and PK profile of rFVIIIFc have been extensively investigated, the structural implications of fusing an Fc to the FVIII C2 domain have not been previously reported. The importance of the C2 domain in mediating interactions between FVIII and both phospholipids and VWF is well documented [16–18]. Electron microscopy (EM) studies have provided a first glimpse of the FVIII–VWF complex structure, and corroborated previous findings that the C1 domain of FVIII is the primary interaction site for VWF, with the C2 domain playing an ancillary role [19,20]. Additionally, the C2 domain has been shown to be immunodominant, with many neutralizing antibodies targeting this domain having been identified in inhibitor patient plasmas [21,22]. These antibodies interfere with the ability of FVIII to bind VWF and phospholipids, or slow the release of thrombin-activated FVIII from VWF, thereby inhibiting its activity. In contrast, rFVIII(Fc) retains normal VWF and phospholipid binding, and also retains the molar specific activity of unmodified FVIII.

To reconcile these observations, we assessed the structure of the individual FVIII and Fc components of rFVIII(Fc) and the spatial relationship between them with a variety of orthogonal methods. Our studies show that the appended Fc does not alter the structure of the FVIII portion of rFVIII(Fc), and that these two elements are flexibly tethered, allowing for translational and rotational freedom about the FVIII–Fc fusion site.

Materials and methods

Protein expression and purification

rFVIII(Fc) was expressed in HEK293 cells and purified as described previously [11,23,24]. Recombinant human BDD factor VIII (rFVIII) was expressed and purified as described previously [23], loaded onto a trimethylaminoethyl column (Fractogel EMD TMAE HiCap [M]; EMD Millipore, Billerica, MA, USA), and eluted with a linear NaCl gradient (75 mM to 0.75 M). Recombinant human IgG1 Fc domain (rFc) was expressed by transient transfection of HEK293 cells, and purified by affinity chromatography on a MabSelect SuRe column (GE Healthcare, Piscataway, NJ, USA) and size-exclusion chromatography on a Superdex 200 column.

ESH8 mAb (Sekisui Diagnostics, Stamford, CT, USA) was cleaved with papain (Roche, Indianapolis, IN, USA), and purified by size-exclusion chromatography on a Superdex 200 column. GMA-8014 Fab and GMA-8008 Fab were purchased from Green Mountain Antibodies (Burlington, VT, USA).

Hydrogen–deuterium exchange mass spectrometry (HDX-MS)

rFVIII(Fc), rFVIII and rFc were dialyzed against 10 mM histidine (pH 7.0), 5 mM CaCl₂, 200 mM NaCl, and 13.3 g L⁻¹ sucrose. Deuterium exchange was initiated by diluting each sample 10-fold with deuterated buffer (99.99% D₂O; Cambridge Isotope Laboratories, Andover, MA, USA) to a final volume of 25 µL. After 10 s, 1 min, 10 min, 1 h and 4 h of incubation, the reaction was quenched, and the protein was denatured and reduced by addition of ice-cold quench solution (1 : 1, v/v) containing 7.5 M guanidinium hydrochloride, 0.2 M Tris(2-carboxyethyl)phosphine, and 0.5 M citric acid, resulting in a pH of 2.3. This preparation was digested on an immobilized pepsin column (Life Technologies, Carlsbad, CA, USA) inside a Waters HDX manager with the temperature maintained at 0 °C. Eluted peptides were desalted, separated on an HSS T3 C18 HPLC column, and introduced into a Synapt G2S mass spectrometer by electrospray ionization. Mass spectra were collected in triplicate for each exchange period. Peptides were identified by use of PROTEINLYNX GLOBAL SERVER (Waters, Milford, MA, USA) inside a Waters HDX manager with the temperature maintained at 0 °C.

X-ray crystallography

Crystallization and data collection rFVIII(Fc) was dialyzed into 25 mM HEPES (pH 7.5), 550 mM NaCl, and 5 mM CaCl₂, and concentrated to 8 mg mL⁻¹. Crystalization was performed with the nanodroplet vapor diffusion method at 4 °C by mixing 200 nL of protein solution with 200 nL of the reservoir solution containing 5% ethanol and 100 mM Tris (pH 7.3). Crystals were cryoprotected by gradual addition of propanediol to the reservoir liquor to 25% (v/v) without ethanol, and flash-frozen in liquid nitrogen. Diffraction data were collected.
at the Advanced Photon Source (APS) at Lilly Research Laboratories Collaborative Access Team (LRL-CAT) at \(-173\) °C with the MAR225 CCD detector.

**Structure determination and refinement** Data reduction was carried out with \textit{hkxl2000} [26]. The space group was \textit{P}4_{1}2_{1}2_{1}. The rFVIII\textsubscript{Fc} structure was solved by molecular replacement with the program \textit{phaser} [27] and the FVIII crystal structure (Protein Data Bank [PDB] code 2R7E [28]) as the search model. \textit{coot} [29] was used for model building, and \textit{refmac5} was used for refinement with external restraints from the initial search model as a reference structure by the use of \textit{prosmart} [30–32]. For later stages of refinement, TLS refinement [33] with anisotropic motion tensors was used. Figures were prepared with \textit{pymol} [34]. Data collection and refinement statistics are summarized in Table S1.

**Small-angle X-ray scattering (SAXS) data collection and evaluation**

SAXS data of freshly gel-filtered samples were collected at ALS beamline 12.3.1 (Lawrence Berkeley National Laboratory, Berkeley, CA, USA) [35,36]. The wavelength was set to 1.03 A, and the sample-to-detector distance to 1.5 m, resulting in scattering vectors, \(q\), ranging from 0.01 A\(^{-1}\) to 0.32 A\(^{-1}\). Experiments were performed at 15 °C, and data were processed as described previously [36]. Briefly, the data acquired at five exposures (0.5, 0.5, 2, 5 and 0.5 s) were merged for calculations using the entire scattering profile. The experimental SAXS curves for different time exposures were investigated for aggregation by the use of Guinier plots [37]. The radius of gyration, \(R\text{\textsubscript{G}}\), was derived by the Guinier approximation \(I(q) = I(0) \exp(-q^2R\text{\textsubscript{G}}^2/3)\) with the limit \(qR\text{\textsubscript{G}} < 1.6\) (Fig. S1). The program \textit{scatter} was used to compute the experimental and models pair distance distribution functions, \(P(r)\) (Fig. S1B,C), providing the maximum dimension of the macromolecule, \(D\text{\textsubscript{max}}\). Data collection details and SAXS parameters are listed in Table S2. Theoretical scattering profiles were calculated with \textit{roxs} [38]. With a rigid-body modeling strategy, BILBOMD, simulations were used to explore the conformational space adopted by the C-terminally fused \(\text{Fc}\) domain. A minimal ensemble search (MES) was used to identify the minimal ensemble required to best fit the experimental data [39].

**EM**

**Image acquisition** An rFVIII\textsubscript{Fc} sample was adsorbed to glow-discharged, carbon-coated grids, and negatively stained as described previously [40]. Low-dose images were collected with a \(4K \times 4K\) CCD camera (Gatan, Pleasanton, CA, USA) on a Tecnai T12 electron microscope (FEI, Hillsboro, OR, USA) operated at an acceleration voltage of 120 kV. The calibrated magnification was \(\times 70\ 527\) (nominal magnification of \(\times 52\ 000\)), yielding a pixel size of 2.13 A at the specimen level. The defocus was set to \(-1.5\) μm. Specimen areas used for three-dimensional (3D) reconstructions were imaged twice, first at a tilt angle of 60° and then again untilted (Fig. S2).

**Image processing** The \textit{spider} software [41] was used to select 16 158 particle pairs from 112 image pairs, which were windowed into 128 \(\times\) 128-pixel images. For the iterative stable alignment and clustering (ISAC) algorithm [42] implemented in \textit{sparx} [43], the particle images from the tilted specimen were reduced to 64 \(\times\) 64 pixels. With specification of 50 images per group and a pixel error threshold of 0.7, 25 generations of ISAC yielded 475 classes (Fig. S3), accounting for 9284 particles (57.5% of the entire dataset). To visualize the mobility of the \(\text{Fc}\) domain, selected ISAC averages were aligned to each other, ordered according to their correlation coefficients, and used to prepare Movie S1.

For 3D reconstruction, the particle images from the untitled specimen were subjected to 10 cycles of reference-free alignment and conventional \(K\)-means classification into 100 classes in \textit{spider}. From the resulting class averages (Fig. S4A), seven averages were used as references for one cycle of supervised classification (Fig. S4B). The particles from the tilted specimen of the resulting groups were used to calculate random conical tilt 3D reconstructions [44] that were refined with projection matching [45], resulting in six interpretable density maps with resolutions from 2.5 nm to 3 nm according to the Fourier shell correlation = 0.5 criterion [46] (Fig. S5). The UCSF \textit{chimera} software [47] was used to visualize the 3D maps and to place the crystal structures of FVIII (PDB code 3CDZ) and Fc (PDB code 1HZH) into the maps (Fig. S6).

For rFVIII–Fab complexes, \textit{boxer} of the \textit{eman} software package [48] was used to select 5013 particles from 45 images for 1B5 (GMA-8008), 5250 particles from 20 images for 3G6 (GMA-8014), and 5103 particles from 50 images for ESH8. The particles were windowed into 120 \(\times\) 120-pixel images, and subjected to 10 cycles of reference-free alignment and \(K\)-means classification into 25 classes in \textit{spider}.

**Surface plasmon resonance (SPR) analysis**

The affinities of rFVIII and rFVIII\textsubscript{Fc} for mAbs 1B5 (GMA-8008), 3G6 (GMA-8014) and ESH8 were determined by ‘one-shot’ kinetics with a ProteOn XPR36 interaction array system (BioRad, Hercules, CA, USA) [49]. Briefly, goat \(\alpha\)-mouse antibody (Jackson ImmunoResearch, West Grove, PA, USA) at a concentration of 30 μg mL\(^{-1}\) in 10 mM sodium acetate (pH 5) was immobilized in channels of a GLC sensor chip (BioRad) by EDC/Sulfo-NHS amine coupling followed by blocking with ethanolamine. All three anti-FVIII antibodies were subsequently captured to a level of \(\sim 70\) resonance units.
Each of the BDD rFVIII and rFVIIIFc analytes was applied in a direction perpendicular to that used for the capture of the antibodies at concentrations of 0.07, 0.2, 0.6, 1.8 and 5.4 nM in phosphate-buffered saline (pH 7.4) containing 0.005% Tween-20 (PBST) for 6 min, and this was followed by a dissociation phase (in PBST alone) of 29 min. Binding experiments were performed in triplicate at a flow rate of 30 μL min⁻¹ at 25 °C on the same sensor chip. Raw data were processed by buffer blank subtraction and interspot referencing, and kinetic parameters were derived with the Proteon Manager software by applying a 1 : 1 interaction model that yielded values for \( \chi^2/R_{\text{max}} \) of 0.05 or less.

**Results**

HDX-MS of rFVIIIFc, rFVIII, and Fc

HDX-MS was performed with rFVIIIFc, rFVIII and Fc to determine whether the fusion of Fc to FVIII results in the structural perturbation of either component. Peptide coverage ranged from 87% to 97% (Fig S7), and the deuterium exchange of the FVIII and Fc portions of rFVIIIFc was compared with that of the isolated constituents (Fig. 1). On the basis of established criteria [25], no regions of differential deuterium exchange were found to be statistically significant, indicating that the structure of FVIII is unaffected by C-terminal Fc fusion. Notably, the lack of differential deuterium exchange proximal to the fusion site implies that Fc neither directly abuts FVIII nor distorts its tertiary structure.

X-ray crystallography of rFVIIIFc

We crystallized rFVIIIFc, which consists of a heavy chain (domains A1 and A2) and a light chain (domains A3, C1, and C2) of FVIII, and a monomeric Fc fused to the C terminus of the C2 domain. The C-terminal Fc fusion forms a dimer with a separately expressed monomeric Fc domain to form the full assembly. At 4.2Å resolution, the overall structure of BDD FVIII in rFVIIIFc, and that of each of its five individual domains, were similar to the previously solved structures of BDD FVIII alone (PDB code 2R7E, 3.7Å resolution [26]; PDB code 3CDZ, 3.98Å resolution [41]), and superimposed with a root mean square deviation of 0.83–1.58 Å (Fig. 2A; Table 1). The most significant differences between structures were found in loop regions, and several loops have, in fact, been omitted from both published structures and from our rFVIIIFc structure, owing to poor electron density. Furthermore, the locations of bound metal ions and glycosylation sites were also conserved, as previously shown [11]. Whereas the heavy chain, light chain–Fc fusion and monomeric Fc were all present in the crystal (Fig. S8), no electron density was observed for Fc, indicating that it was disordered in the crystal lattice. Analysis of the crystal packing revealed a large solvent channel (approximately 60 × 70 × 75 Å) located at the C terminus of the C2 domain, where Fc is expected to be (Fig 2B). The channel was sufficient in volume to accommodate the various Fc conformations observed with SAXS and EM (see below). In Fig. 2B, we have modeled one such conformation by using one of the positions of Fc seen in the EM maps, illustrating that Fc can easily fit into the solvent channel. Taken together, these data suggest that Fc does not alter the atomic structure of FVIII, but rather is flexibly tethered to FVIII.

SAXS of rFVIII and rFVIIIFc

To assess the structural dynamics of rFVIIIFc in solution, we collected and analyzed SAXS curves of rFVIII and rFVIIIFc (Fig. 3A,B). The SAXS profile and linear Guinier plot [37] of rFVIII alone indicated that the protein does not aggregate in solution (Fig. S1A). The pair distribution function \( P(r) \) (Fig. 1B) and experimental SAXS curve of rFVIII matched the theoretical \( P(r) \) and SAXS profile calculated from an rFVIII model generated by modeling missing loops into the structure of FVIII [28]. Therefore, we also included the missing loops in our solution structure modeling of rFVIIIFc. To examine the flexible character of the appended Fc domain in rFVIIIFc, we used rigid-body modeling by BILBOMD [39]. An initial rFVIIIFc model was built by fusing the structure of the human IgG1 Fc domain [50] to the rFVIII model described above. A large set of models that represent possible structures of rFVIIIFc were then generated by allowing the FVIII and Fc portions of rFVIIIFc to move as rigid bodies relative to one another. From these models, theoretical SAXS curves were calculated and compared with the experimental curve collected for rFVIIIFc by the use of previously published methods [38]. From all modeled conformers, the best-fitting structure (\( \chi = 1.6 \)) (Fig. 3B) positioned Fc in an extended conformation away from FVIII, consistent with the maximal dimension observed in the \( P(r) \) (Fig. S1C). Reconstruction of a single best model for flexible proteins can be misleading and, at best, provides an average of the conformations [51]. Taking into account the likely coexistence of different conformations of the rFVIIIFc fusion protein, we applied the MES approach to identify the minimal ensemble required to best fit the experimental data [39]. The resulting ensemble model, consisting of three conformers (Fig. 3C), improved the match of the \( P(r) \) functions (Fig. S1C) and SAXS profiles (\( \chi = 1.4 \)), particularly in the low-resolution \( q \) range (\( q < 0.1 \text{ Å}^{-1} \)) (Fig. 3B). These results indicate a high degree of conformational variability about the FVIII–Fc fusion site.

EM of rFVIIIFc

We used negative-stain EM to visualize rFVIIIFc. The relative positions of the FVIII domains were the same in
all class averages (Fig. 4A; Fig. S3), but the angle between Fc and FVIII varied greatly. Most averages showed Fc located close to the C2 and A1 domains of FVIII, but a few showed that Fc can also move to a position below the C1 and C2 domains. Furthermore, Fc can be seen in ‘front’ and ‘side’ views, indicating that there is
EM and SPR analysis of Fab and antibody binding to FVIII

Antibodies against the FVIII C2 domain have been extensively characterized, owing to the prevalence of neutralizing alloantibodies directed against the C2 domain in individuals with hemophilia A who develop inhibitors as a consequence of FVIII replacement therapy [21]. Anti-C2 antibodies have also been used to study the role of the C2 domain in the association of FVIII with phospholipid surfaces and VWF, and in the proteolytic activation of FVIII by thrombin and activated FX (FXa). These antibodies have been categorized into five groups (A, AB, B, BC, and C) on the basis of their respective epitopes, and characterized with regard to their ability to inhibit FVIII activity, phospholipid binding, and VWF binding [21]. More recently, the epitopes of several of these antibodies were fine-mapped by scanning mutagenesis and affinity analysis by SPR [52]. Of these, we selected three antibodies with a range of inhibitory activities and epitopes with varying proximities to the Fc domain fusion site at the C terminus of rFVIIIFc: 1B5 (group B, alias GMA-8008), 3G6 (group BC, alias GMA-8014), and ESH8 (group C) (Fig. 5A). The structures of BDD FVIII in complex with Fab fragments from each of these antibodies were determined by negative-stain EM. Representative class averages (Fig. 5B; see Fig. S9 for all averages) are consistent with previously reported epitopes [52], and indicate varying degrees of conformational flexibility about the FVIII–Fab axis for 1B5 (moderate), 3G6 (low), and ESH8 (moderate). Despite this positional variability, the locations of Fab fragments coincide spatially with areas occupied by the Fc domain of rFVIIIFc as determined here by SAXS (Fig. 3C) and EM (Fig. 4; Movie S1).

The relative affinities of each of these antibodies for BDD rFVIII and rFVIIIFc were determined by SPR. Representative sensorgrams (Fig. 5C) illustrate qualitatively similar dissociation and association kinetics for BDD rFVIII and rFVIIIFc for each antibody, consistent with similar $K_D$ values for each pair of interactions (Table 2). We therefore conclude that BDD rFVIII and rFVIIIFc are similarly able to accommodate the binding of these three anti-C2 antibodies, confirming that the linkage between FVIII and Fc in rFVIIIFc is highly flexible, and that the tethered Fc is relatively unconstrained.

Discussion

Long-acting FVIII molecules allow the achievement of higher factor activity levels and/or less frequent intravenous administration, and represent one the most significant improvements in the prevailing standard of care for patients with hemophilia A in > 20 years. In addition to Fc fusion, current strategies for extending the half-life of FVIII include chemical conjugation of PEG adducts to FVIII by a variety of methods [53]. Regardless of the

Table 1 Cz root mean square deviation (RMSD) values of FVIII structures (Å)

<table>
<thead>
<tr>
<th></th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>C1</th>
<th>C2</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>rFVIIIFc: 2R7E</td>
<td>0.84</td>
<td>0.83</td>
<td>0.84</td>
<td>0.90</td>
<td>0.87</td>
<td>1.02</td>
</tr>
<tr>
<td>rFVIIIFc: 3CDZ</td>
<td>1.43</td>
<td>1.35</td>
<td>1.26</td>
<td>1.08</td>
<td>0.92</td>
<td>1.58</td>
</tr>
<tr>
<td>2R7E: 3CDZ</td>
<td>1.59</td>
<td>1.91</td>
<td>1.51</td>
<td>1.20</td>
<td>1.09</td>
<td>1.59</td>
</tr>
</tbody>
</table>

rFVIIIFc, recombinant human B-domain-deleted FVIII Fc.

also rotational freedom of Fc relative to FVIII. Movie S1 illustrates the substantial mobility of Fc relative to FVIII.

Next, 3D maps of rFVIIIFc were created by using the random conical tilt reconstruction method, and these showed flexibility of Fc similar to that seen in the two-dimensional averages (Fig. 4B). Placement of the crystal structures of FVIII [28] and Fc [50] into the 3D maps yielded models of the intact rFVIIIFc molecule (Fig. 4C). These data confirm that Fc is flexibly tethered to FVIII.

Fig. 2. Crystal structure of recombinant factor VIII Fc (rFVIIIFc). (A) Superposition of the FVIII component of rFVIIIFc (blue) with two previously solved structures of B-domain-deleted FVIII (Protein Data Bank [PDB] code 2R7E, green; PDB code 3CDZ, orange) is shown in two views rotated by 180°. No electron density was observed for Fc, suggesting that it is not ordered in the crystal lattice. (B) The FVIII element of rFVIIIFc is shown in surface representation, with its constituent domains shown in different colors (A1, red; A2, orange; A3, green; C1, blue; C2, purple). Symmetry mates of FVIII are also shown in surface representation, and colored white, gray, and light blue, and reveal the presence of large solvent channels (left panel). One Fc conformation is modeled according to the position of Fc from one of the EM structures (right panel). The Fc is shown in surface representation, and symmetry mates are shown in cartoon representation.
approach used to extend the half-life of FVIII, a detailed analysis of the 3D structure of the resulting molecule is essential to ensure the absence of structural perturbations that could alter its specific activity or bioavailability relative to the original FVIII molecule, or promote the formation of neo-epitopes that could have immunogenic...
consequences. For rFVIIIFc, these concerns have been allayed, in part, by several key findings. First, the specific activity of rFVIIIFc and its affinity for VWF are indistinguishable from those of BDD rFVIII [11]. Second, in hemophilia A mice, rFVIIIFc shows reduced immunogenicity relative to BDD rFVIII and full-length rFVIII, and even induces a tolerogenic response [54]. Finally, no incidences of inhibitor formation were observed in the rFVIIIFc pivotal phase 3 (A-LONG) trial in previously treated patients [13] or in a subsequent clinical trial of 71 previously treated pediatric patients (Kids A-LONG) [55]. These observations suggest structural comparability between the FVIII component of rFVIIIFc and otherwise unmodified FVIII, consistent with our finding that the structure of the FVIII component of rFVIIIFc is indistinguishable from two previously published FVIII structures [28,56]. This conclusion is further strengthened by our HDX-MS analysis, which revealed no statistically significant differences in deuterium uptake within 416 individual peptides representing 94% sequence coverage of the FVIII component of rFVIIIFc or within 50 peptides representing 87% sequence coverage of its Fc domain (Fig. S7).

Our HDX-MS and X-ray crystallographic data also provide insights into the nature of the Fc linkage to FVIII in rFVIIIFc. The lack of differential deuterium uptake between FVIII with and without the appended Fc domain suggests that any interactions that might occur in solution between Fc and FVIII are sufficiently transient in nature so as to not perturb deuterium uptake in either component when tethered. The lack of visible electron density for Fc in the rFVIIIFc crystal also implies that Fc adopts various orientations relative to FVIII. These results are consistent with the known structural dynamics of intact human IgG1 molecules. The flexibility of different IgG subclasses is a function of the sequence and length of the Fab–Fc hinge region [57], and the human IgG1 subclass shows the most interdomain flexibility, with Fab–Fc angles ranging from 60° to 160° [58]. We employed SAXS analysis to evaluate the flexibility of the corresponding FVIII–Fc junction, and found that a similar range of flexibility in solution was shown by the resulting ensemble model, a finding that was corroborated by negative-stain EM analysis.

We further assessed the dynamics of the FVIII–Fc junction by comparing the affinities for rFVIII/rFVIIIFc of

Fig. 4. Single-particle electron microscopy (EM) analysis of negatively stained recombinant factor VIII Fc. (A) Representative class averages obtained with the iterative stable alignment and classification procedure (see Fig. S3 for all averages). The side length of the individual panels is 27.3 nm. (B) 3D maps of six classes. (C) Superposition of models obtained by placing atomic models of FVIII and Fc into EM density maps 1 and 4 (top) and 6 and 4 (bottom). The atomic model of FVIII (Protein Data Bank [PDB] code 3CDZ) is shown in blue, and the atomic models of Fc (PDB code 1HZH) placed into volumes 4, 1 and 6 are shown in green, red, and orange, respectively. Scale bars in (B) and (C): 5 nm.

Fig. 5. Binding of ESH8, GMA-8014 and GMA-8008 to recombinant factor VIII (rFVIII) and recombinant FVIII Fc (rFVIIIFc). (A) The epitopes on FVIII of three different anti-C2 antibodies are highlighted in yellow (FVIII domains are colored as in Figure 2, with the C terminus in cyan). (B) Representative class averages of negatively stained B-domain-deleted rFVIII in complex with the Fab of each antibody show that these antibodies bind to FVIII in a position similar to that occupied by Fc in rFVIIIFc (Fig. 4). See Fig. S9 for all class averages. The side length of the individual panels is 27.3 nm. (C) The affinities of each antibody for rFVIII and rFVIIIFc were determined by surface plasmon resonance in triplicate, and indicate that the presence of Fc in rFVIIIFc does not affect the binding of these antibodies to FVIII. RU, resonance units.
A 1B5 3G6 ESH8

Side

Front

B A2 A3 A1 C1 C2

FVIII-Fab

C rFVII

K_D = 7.92 \times 10^{-11} M

K_D = 1.24 \times 10^{-10} M

K_D = 1.16 \times 10^{-10} M

rFVIIIc

K_D = 5.71 \times 10^{-11} M

K_D = 1.31 \times 10^{-10} M

K_D = 1.50 \times 10^{-10} M
three well-characterized anti-C2 antibodies, each with distinctly different epitopes, inhibitory activities, and potencies for inhibiting the association of FVIII with phospholipid surfaces and VWF. It is of particular note that antibody 1B5 potently inhibits both phospholipid and VWF binding by FVIII, consistent with the mapping of its epitope to the phospholipid-binding ‘feet’ of the C2 domain [52], whereas antibody 3G6 is a potent type II inhibitor (25 000 Bethesda units mg\(^{-1}\)) that impairs the activation of FVIII by either thrombin or FXa, but causes only slight inhibition of FVIII binding to either phospholipid or VWF [21]. Each antibody showed similar affinities for FVIII and rFVIIIFc, demonstrating that, despite the proximity of their respective epitopes to the FVIII–Fc junction (29 Å for 1B5; 17 Å for 3G6; and 19 Å for ESH8) and the distinctly different mechanisms underlying their inhibition of FVIII procoagulant activity, the appended Fc domain of rFVIIIFc did not sterically interfere with their binding to the FVIII C2 domain. These findings support the conclusion that the Fc domain of rFVIIIFc dynamically samples a wide range of conformational space in relation to FVIII, as illustrated in Movie S1. This evidence of flexible tethering and the demonstration that the FVIII and Fc components of rFVIIIFc are structurally indistinguishable from their isolated counterparts provide a structural rationale for the previously reported functional comparability of FVIII and its long-acting variant, rFVIIIFc.

Acknowledgements

The authors thank A. Mezo, D. Light, J. Arndt, G. Pierce, and J. Tainer for their contributions. Use of the APS was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. Use of the LRL-CAT beamline facilities at Sector 31 of the APS was provided by Eli Lilly & Company, which operates the facility. SIBYLS was supported by the US Department of Energy, Integrated Diffraction Analysis Technologies program and NIH MINOS R01GM105404. Coordinates and structure factors of the rFVIIIFc crystal structure have been deposited in the PDB with accession code 5K8D.

Addendum

J. D. Kulman and R. T. Peters conceived the study. N. C. Leksa, P.-L. Chiu, G. M. Bou-Assaf, C. Quan, Z. Liu, A. B. Goodman, M. G. Chambers, S. E. Tsutakawa, M. Hammel, and T. Walz performed and analyzed experiments. N. C. Leksa, J. D. Kulman, and T. Walz wrote the manuscript with contributions from all authors.

Disclosure of Conflict of Interests

N. C. Leksa, G. M. Bou-Assaf, C. Quan, Z. Liu, A. B. Goodman, R. T. Peters and J. D. Kulman were employees of Biogen at the time of this work. P.-L. Chiu, S. E. Tsutakawa, M. Hammel and T. Walz received funding support from Biogen. This work was funded by Biogen/ Bioverativ.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1. Pair distribution function of rFVIII and rFVIIIFc. (A) The Guinier plots for the experimental SAXS profiles are shown. The magenta line represents the linear fit to the Guinier region with the limit \(q_{RG} < 1.6\) and indicates an aggregation-free state of the samples. (B) Experimental (black) and theoretical (red) \(P(r)\) functions of rFVIII were calculated from the experimental and theoretical SAXS profiles shown in Fig. 3A. (C) Experimental \(P(r)\) function (black) of rFVIIIFc compared to the theoretical \(P(r)\) functions calculated for the best fit model (red) and the ensemble model (green) shown in Fig. 3C.

Fig. S2. Image pair of a specimen area of negatively stained rFVIIIFc recorded at tilt angles of 0° and 60°. The lines indicate the tilt axis. Scale bar indicates 100 nm.

Fig. S3. The class averages of negatively stained rFVIIIFc that were obtained with the iterative stable alignment and classification (ISAC) algorithm. The 16,158 particles selected from the images of untilted specimens were subjected to 25 ISAC generations, yielding 475 class averages. The side length of the individual panels is 27.3 nm.

Fig. S4. The class averages of negatively stained rFVIIIFc that were obtained with K-means classification. (A) The 16,158 particles selected from the images of untilted specimens were subjected to K-means classification into 100 classes. The averages are ordered from the most populated class at the top left to the least populated class at the bottom right. (B) The panels to the left show the seven averages that were chosen as references for supervised classification. The panels to the right show the resulting class averages. The numbers indicate the 3D structure differences.
density maps that are shown in Fig. 4. The side length of the individual panels is 27.3 nm.

Fig. S5. Fourier shell correlation (FSC) curves for the six density maps obtained with negatively stained rFVIII:Fc. According to the FSC = 0.5 cut-off criterion, the resolution of the density maps ranges from 2.5 to 3 nm.

Fig. S6. Placement of FVIII and Fc crystal structures into EM density maps. The crystal structures of FVIII (PDB code: 3CDZ) and Fc (PDB code: 1HZH) were placed into EM density maps 1 (A), 4 (B) and 6 (C). The scale bar is 5 nm.

Fig. S7. rFVIII:Fc peptide coverage map for HDX-MS. The sequences of the FVIII-Fc monomer (A) and the separately expressed Fc monomer (B) are shown. Blue bars below the sequence indicate peptides from rFVIII:Fc identified by MS. For FVIII and Fc, 94% and 87% of the expected peptides were recovered, respectively, and used to determine deuterium exchange.

Fig. S8. Silver-stained reducing SDS-PAGE gel of a dissolved rFVIII:Fc crystal. The first lane contains purified rFVIII:Fc prior to crystallization, and the second lane contains a dissolved crystal, confirming the presence of the Fc. All bands are present at the expected relative intensities.

Fig. S9. Negative-stain EM analysis of BDD rFVIII in complex with Fabs of anti-C2 antibodies. (A) Raw image of negatively stained complex of BDD rFVIII with Fabs of EHS8. Scale bar indicates 50 nm. (B-D) The averages that were obtained by K-means classification of negatively stained BDD rFVIII in complex with Fabs of EHS8 (B), Fabs of GMA-8014 (C), and Fabs of GMA-8008 (D). The side length of the individual panels is 25.6 nm.

Movie S1. Mobility of the Fc domain relative to the FVIII component in rFVIII:Fc. Selected ISAC averages of rFVIII:Fc were aligned to one another and ordered according to their correlation coefficients to visualize the flexibility of the appended Fc.

Table S1. Data collection and refinement statistics.

Table S2. Data collection and SAXS parameters.


